Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Martínez-Soldevilla, M. (Mario) | - |
dc.creator | Villanueva, H. (Helena) | - |
dc.creator | Meraviglia-Crivelli, D. (Daniel) | - |
dc.creator | Menon, A.P. (Ashwathi Puravankara) | - |
dc.creator | Ruiz, M. (Marta) | - |
dc.creator | Cebollero, J. (Javier) | - |
dc.creator | Villalba, M. (María) | - |
dc.creator | Moreno, B. (Beatriz) | - |
dc.creator | Lozano-Moreda, T. (Teresa) | - |
dc.creator | Llopiz, D. (Diana) | - |
dc.creator | Pejenaute-Martínez-de-Lizarrondo, Á. (Álvaro) | - |
dc.creator | Sarobe, P. (Pablo) | - |
dc.creator | Pastor, F. (Fernando) | - |
dc.date.accessioned | 2022-03-02T09:06:12Z | - |
dc.date.available | 2022-03-02T09:06:12Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Martínez-Soldevilla, M. (Mario); Villanueva, H. (Helena); Meraviglia-Crivelli, D. (Daniel); et al. "ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity". Molecular Therapy. 27 (11), 2019, 1878 - 1891 | es_ES |
dc.identifier.issn | 1525-0016 | - |
dc.identifier.other | PMID 31405808 | - |
dc.identifier.uri | https://hdl.handle.net/10171/62974 | - |
dc.description.abstract | Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there is still room for improvement in the quest for new therapeutic combinations. ICOS costimulation has been underscored as a possible target to include with CTLA-4 blocking treatment. Herein, we describe an ICOS agonistic aptamer that potentiates T cell activation and induces stronger antitumor responses when locally injected at the tumor site in combination with anti-CTLA-4 antibody in different tumor models. Furthermore, ICOS agonistic aptamer was engineered as a bi-specific tumor-targeting aptamer to reach any disseminated tumor lesions after systemic injection. Treatment with the bi-specific aptamer in combination with CTLA-4 blockade showed strong antitumor immunity, even in a melanoma tumor model where CTLA-4 treatment alone did not display any significant therapeutic benefit. Thus, this work provides strong support for the development of combinatorial therapies involving anti-CTLA-4 blockade and ICOS agonist tumor-targeting agents. | es_ES |
dc.description.sponsorship | This work was supported by a Worldwide Cancer Research grant under grant 15-1208, Melanoma Research Alliance (509510), and Fundación Ramón Areces (CIVP18A3916). Instituto de Salud Carlos III cofunded Fondos FEDER (PI17/00372). F.P. was supported by Ramón y Cajal (10699). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 721358. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier BV | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/721358/EU | - |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Target therapeutics | es_ES |
dc.subject | Cancer immunotherapy | es_ES |
dc.subject | ICOS | es_ES |
dc.subject | CTLA-4 | es_ES |
dc.subject | Aptamer | es_ES |
dc.title | ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | es_ES |
dc.identifier.doi | 10.1016/j.ymthe.2019.07.013 | - |
dadun.citation.endingPage | 1891 | es_ES |
dadun.citation.number | 11 | es_ES |
dadun.citation.publicationName | Molecular Therapy | es_ES |
dadun.citation.startingPage | 1878 | es_ES |
dadun.citation.volume | 27 | es_ES |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.